On Tuesday, August 23, 2022, FIGHT’s Chief Medical Officer, Stacey Trooskin, MD, Ph.D., visited Washington, D.C., to discuss a national strategy for hepatitis C elimination. The meeting was convened at the White House by the Acting Science Advisor to the President, Francis Collins, MD, Ph.D., and brought together critical stakeholders across healthcare and related fields and government officials to work towards eliminating the hepatitis C virus. Dr. Trooskin advocated on behalf of FIGHT as a federally qualified health center in the feds’ implementation of the elimination plan.
Hepatitis C (or HCV) is the most common blood-borne viral infection in the US. If left untreated it can lead to serious liver problems such as cirrhosis or cancer. There are as many as 5 million people in the United States living with Hepatitis C and most people who are living with HCV are unaware they are infected with the virus. According to the Philadelphia Department of Public health, an estimated 53,000 people in Philadelphia are living with HCV. Hepatitis C can be cured and the C a Difference program can assist those living with HCV to obtain subspecialty care. High-quality confidential testing, education, and linkage services are provided in FIGHT’s offices and at various sites throughout the city.